semagacestat

Ligand id: 6978

Name: semagacestat

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 7
Topological polar surface area 98.74
Molecular weight 361.2
XLogP 0.72
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
IUPAC Name
(2S)-2-hydroxy-3-methyl-N-[(2S)-1-[[(1S)-3-methyl-2-oxo-4,5-dihydro-1H-3-benzazepin-1-yl]amino]-1-oxopropan-2-yl]butanamide
International Nonproprietary Names
INN number INN
8996 semagacestat
Synonyms
LY-450139
Comments
Semagacestat is a small-molecule γ-secretase inhibitor that was developed by Eli Lilly as a potential treatment for Alzheimer's disease but it failed in Phase 3 clinical trials. NOTCH is also a γ-secretase substrate [3], and on-target inhibition of NOTCH receptor-related signalling by semagacestat treatment is proposed to be (at least in part) responsible for the unacceptable side effects that were noted in clinical trials, and which lead to termination of the trials [1].
Database Links
CAS Registry No. 425386-60-3 (source: PubChem)
ChEMBL Ligand CHEMBL520733
GtoPdb PubChem SID 178103557
PubChem CID 9843750
Search Google for chemical match using the InChIKey PKXWXXPNHIWQHW-RCBQFDQVSA-N
Search Google for chemicals with the same backbone PKXWXXPNHIWQHW
Search PubMed clinical trials semagacestat
Search PubMed titles semagacestat
Search PubMed titles/abstracts semagacestat
Search UniChem for chemical match using the InChIKey PKXWXXPNHIWQHW-RCBQFDQVSA-N
Search UniChem for chemicals with the same backbone PKXWXXPNHIWQHW
Wikipedia Semagacestat

Product suppliers

View disclaimer

Tocris
LY 450139
Cat. No. 6559